^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD19-targeted CAR-T immunotherapy

    Related drugs:
    4d
    huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, University of Pennsylvania
    New P1 trial
    |
    CD19 (CD19 Molecule)
    |
    huCART19-IL18
    5d
    Tisagenlecleucel in combination with ibrutinib in adults with relapsed and/or refractory large B-cell lymphomas. (PubMed, Blood Neoplasia)
    Altogether, these findings suggest administering ibrutinib before leukapheresis may modify T-cell characteristics in the collected material, thereby improving final CAR T-cell product quality and clinical outcomes for patients with R/R LBLC treated with tisagenlecleucel. This trial was registered at www.clinicaltrials.gov as #NCT03876028.
    Clinical • Journal
    |
    IFNG (Interferon, gamma) • IL2 (Interleukin 2)
    |
    Imbruvica (ibrutinib) • Kymriah (tisagenlecleucel-T)
    6d
    AMC-112: Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=20, Recruiting, AIDS Malignancy Consortium | Trial completion date: Jan 2027 --> Jan 2029 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV
    6d
    Breakfree-SSc: A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacaptagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis (clinicaltrials.gov)
    P3, N=92, Not yet recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
    New P3 trial
    |
    Rituxan (rituximab) • cyclophosphamide • nintedanib • fludarabine IV • Actemra IV (tocilizumab) • BMS-986353
    6d
    Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Medical College of Wisconsin
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    7d
    Impact of CD5 expression on outcomes for chimeric antigen receptor-T cell therapy in relapsed and refractory diffuse large B-cell lymphoma. (PubMed, Cytotherapy)
    To investigate this clinical issue, 106 patients treated with CAR-T cell therapy using either tisagenlecleucel, lisocabtagene maraleucel or axicabtagene ciloleucel for r/r DLBCL at our institution were retrospectively analyzed. Multivariate analysis revealed that CD5 expression was unfavorably associated with PFS and OS. Together, these data suggest that CD5 expression has a negative impact on outcomes after CAR-T cell therapy.
    Journal • IO biomarker
    |
    CD5 (CD5 Molecule)
    |
    Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T)
    7d
    Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE (clinicaltrials.gov)
    P1, N=18, Recruiting, Chongqing Precision Biotech Co., Ltd
    New P1 trial
    |
    puzolcabtagene autoleucel (pCAR-19B)
    7d
    CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL (clinicaltrials.gov)
    P1, N=5, Terminated, Medical College of Wisconsin | N=24 --> 5 | Trial completion date: Jun 2026 --> Sep 2025 | Suspended --> Terminated; Low accrual
    Enrollment change • Trial completion date • Trial termination
    |
    CD20 positive
    |
    CAR-20/19-T Cells
    7d
    A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lymphoblastic Leukemia/Lymphoma Who Are Intolerant to Intensive Chemotherapy (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, Zhujiang Hospital
    New P1 trial
    |
    cyclophosphamide • fludarabine IV
    8d
    A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune Diseases (clinicaltrials.gov)
    P1, N=22, Recruiting, Grit Biotechnology
    New P1 trial
    |
    MPO (Myeloperoxidase)
    10d
    Clinical Study of LV009 Injection in the Treatment of Recurrent/Refractory CD19 Positive Blood Tumors (clinicaltrials.gov)
    P1, N=19, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P1 trial
    |
    CD19 positive
    10d
    A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Calibr, a division of Scripps Research | Initiation date: May 2025 --> Feb 2026
    Trial initiation date
    |
    cyclophosphamide • CLBR001/SWI019